-       Report 
- May 2025
-  240 Pages 
- Global 
   From       €4292EUR$4,799USD£3,776GBP 
          -       Report 
- June 2025
-  400 Pages 
- Global 
   From       €4427EUR$4,949USD£3,894GBP 
          -       Report 
- March 2024
-  110 Pages 
- Global 
   From       €5322EUR$5,950USD£4,681GBP 
          -       Report 
- October 2023
-  145 Pages 
- Global 
   From       €2818EUR$3,150USD£2,478GBP 
            -       Report 
- September 2022
-  30 Pages 
- Global 
   From       €1968EUR$2,200USD£1,731GBP 
      €2460EUR$2,750USD£2,164GBP 
           -       Report 
- February 2024
-  70 Pages 
- Global 
   From       €4249EUR$4,750USD£3,737GBP 
          -       Report 
- May 2024
-  200 Pages 
- Global 
   From       €3712EUR$4,150USD£3,265GBP 
          -       Report 
- October 2023
-  140 Pages 
- Global 
   From       €3980EUR$4,450USD£3,501GBP 
            -       Report 
- September 2022
-  342 Pages 
- Global 
   From       €6798EUR$7,600USD£5,980GBP 
      €8497EUR$9,500USD£7,475GBP 
             Qsymia is a prescription anti-obesity drug developed by VIVUS, Inc. It is a combination of two active ingredients, phentermine and topiramate, which work together to reduce appetite and increase satiety. The drug is approved by the US Food and Drug Administration (FDA) for the treatment of obesity in adults. Qsymia is available in two dosage strengths, 3.75 mg/23 mg and 7.5 mg/46 mg.
Qsymia is one of several anti-obesity drugs on the market. Other drugs include Belviq, Contrave, Saxenda, and    Xenical. These drugs are used to help people lose weight and reduce the risk of obesity-related health problems.
Companies in the Qsymia market include VIVUS, Inc., Arena Pharmaceuticals, Orexigen Therapeutics, Inc., and Eisai Co., Ltd. Show Less   Read more